World Pharma Contract Sales Industry and Market: Predictions 2014-2024

世界の医薬品受託販売業界および市場(2014-2024)

◆タイトル:World Pharma Contract Sales Industry and Market: Predictions 2014-2024
◆商品コード:Visiongain-4052628
◆調査・発行会社:visiongain
◆発行日:2014年2月
◆ページ数:210
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の医薬品受託販売業界および市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場の促進要因、抑制要因、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、セグメント別市場分析、専門家の見解、結論などの情報をお届けいたします。

Outsourced selling of medicines – how to find trends, opportunities, and revenue prospects
What’s the future of outsourcing pharma sales activities? Now you can get new forecasts for contracted promotional activities for prescription drugs. Stay ahead, then, for data. There you explore business results, developments, trends, opportunities, and predicted revenues.
Visiongain’s new report shows you what’s possible in those services for pharmaceuticals. Avoid missing out or losing authority. Instead you get financial analysis for that industry and market, discovering outlooks. Find progress in detailing and hear about the expected gains.
Read on to explore that contract healthcare sector, seeing what its future could be worth.
Knowledge to help your work and save time, benefiting your influence
Our study shows you trade predictions to 2024 at overall world, submarket, and national level. For those service offerings you investigate where money lies. Find what’s possible.
Ever had trouble getting data you need? Yes, that’s frustrating. Instead see how our report helps your research, analyses, and decisions for medical sales. Save time, too, and stay ahead. Also benefit your authority through better understanding the present and future.
Forecasts and other information showing opportunity in that pharmaceutical contracting
Besides forecasting revenues to 2024, that new work shows historical performance, recent results, growth rates, and market shares. There you get feel for companies’ outlooks and potentials. You also gain 74 tables, 67 charts, and three interviews with that industry.
And the following sections explain in more detail what you get in the new investigation.
Forecasting of that world market and its main segments – what’s likely to happen?
What’s that industry’s potential? What’re the secrets of its progress? Discover in our report overall world revenue to 2024 for contract pharma sales operations.
Also see individual predictions of revenues to 2024 for ten submarkets at world level:
• Cardiovascular disease therapies
• Metabolic disorder treatments
• Cancer-treating agents
• Detailing
• Non-personal promotion.
And get forecasts for these fields and sub-analyses:
• Teledetailing
• Edetailing
• Medical education roles
• Sample management services
• Other related applications.
There you assess outlooks for business, hearing where you can gain. So investigate competition and rising sales. And discover lucrative possibilities there for syndicated pharma sales teams.
That work also shows you geographical predictions.
Healthcare in national markets – outlooks for contracted medical sales
Progress worldwide in healthcare expands use of contracted services for selling and promoting medicines to doctors and other drug prescribers.
You hear about the best revenue prospects for those outsourced and off-shored operations, appraising national opportunities. See where and how you could profit.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• Germany, France, UK, Italy, and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India, and China (BRIC nations).
There you find countries with highest revenues, demands, and potential sales growth. Stay ahead, then, for information. You find international prospects for promoting and selling to medical practitioners.
And what events change that market? Our work shows you, discussing trends and needs.
Developments, challenges, and effects influencing contract sales organisations (CSOs)
The report also explains issues, forces, and events affecting the CSO industry and market from 2014:
• Numbers of contract and in-house sales reps – trends and emerging sales models
• Services CSOs offer and benefits to drug companies outsourcing pharma sales
• Maturing brands and product launches, inc. flexibility in field sales teams
• Physician payment legislation in the US, Europe, and Japan, and new market access requirements for pharma sales representatives – regulatory outlooks
• Changes to online marketing rules for prescription drugs
• Multichannel marketing, key account management (KAM), key opinion leaders (KOLs), and medical science liaison (MSL).
And you explore these influences, among others:
• Smartphones and tablets for new detailing strategies – advances in technology
• Closed loop marketing (CLM), cloud computing, and customer relationship management (CRM), inc. social media use and big data
• Cuts to in-house sales staff – implications for outsourcing service providers
• Strategic partnering and CSO consolidation – networks, links and alliances
• Needs for biological drugs (biologics), biosimilars, and other specialty medicines (with overall world revenue predictions to 2024 for biologics and biosimilars).
There you find what stimulates and restrains players in that industry, and affects its results.
Analysis of companies and potential for market growth – what’s possible from 2014?
Our study predicts the world market for pharma contract selling will reach $5.9bn in 2018.
There large pharma service contractors and specialists can profit, expanding business from 2014 to 2024. The new analysis shows you gains possible.
So what happens next? In particular, our report assesses these companies’ activities:
• Quintiles
• inVentiv Health
• UDG Healthcare
• PDI
• Publicis Touchpoint Solutions
• OnCall.
There you analyse participants’ results, capabilities, and outlooks. You also read three interviews with firms in the industry. Discover what pharma outsourcing providers do, say, and think, helping you stay ahead.
Ways World Pharma Contract Sales Industry and Market: Predictions 2014-2024 helps
Through knowledge such as this, our new report helps you get recognition for insight:
• Revenues there to 2024 at world level, with forecasts for 10 submarkets – assess prospects for investments, marketing, and revenues
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – investigate developed and developing countries for commercial potentials
• Outlooks for established, rising, and emerging service providers – explore results, capabilities, news, technologies, portfolios, and strategies.
Knowledge found nowhere else, helping your searches, analyses, and plans
Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.
So with our data you’re less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our study how you could save time and effort. Also help your planning, decisions, competing, and authority.
Predictions for outsourced pharma selling – gain by trying our report now
This new report is for everyone investigating medical promotions and selling. There you find revenue forecasting to 2024, with discussions. Avoid missing out – please order it now.

【レポートの目次】

1. Executive Summary
1.1 Pharma Contract Sales: World Market Review 2013
1.2 Report Contents
1.2.1 Benefits of the Report
1.3 Report Methodology
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.3.3 Defining the Pharma Contract Sales Market
1.4 An Introduction to Pharma Contract Sales
1.4.1 Pharma Sales Models 2013
1.4.1.1 Detailing Healthcare Professionals
1.4.2 There Are Benefits to Outsourcing Pharma Sales
1.4.2.1 What Services Do CSOs Offer?
1.4.2.2 The Rise in Pharma Contract Sales
1.4.3 The Need for New Sales Models
2. World Pharma Contract Sales Market: Outlook and Forecast 2014-2024
2.1 World Pharma Contract Sales Market 2012-2013
2.1.1 Pharma Contract Sales Market by Sector 2012-2013
2.1.2 Recent Growth in Outsourced Pharma Sales
2.2 World Pharma Contract Sales Market Forecast 2014-2024
2.2.1 Maturing Brands and New Product Launches to Drive Growth to 2024
2.2.2 Pharma Contract Sales: Market Restraints 2014-2024
2.3 Leading Therapeutic Areas for Pharma Contract Sales 2014-2024
2.4 Contract Sales for Cardiovascular Drugs 2014-2024
2.4.1 Growth for Cardiovascular Disease Services: Submarket Forecast 2014-2024
2.5 Metabolic Disorders: Pharma Contract Sales 2014-2024
2.5.1 Metabolic Disorder Services: New Obesity and Diabetes Product Launches Drive to Growth 2014-2024
2.6 Contract Sales for Cancer Drugs 2014-2024
2.6.1 Oncology Sales Services: Submarket Forecast 2014-2024
2.7 Chapter Summary: Strong Growth Forecast for the Pharma Contract Sales Market 2014-2024
3. Leading Service Sectors of the Pharma Contract Sales Market 2014-2024
3.1 Detailing Leads the Contract Sales Market 2013
3.1.1 Rising Demand for Inside and Outside Sales Teams
3.2 Personal Promotion: Contract Detailing Submarket 2014-2024
3.2.1 Detailing Services Offered by CSOs
3.2.2 Contract Detailing: Submarket Forecast 2014-2024
3.2.3 CSOs Are Affected by Doctor Access as Much as Internal Reps
3.2.4 Field Sales Flexibility to Drive Submarket Growth 2014-2024
3.3 Contract Non-Personal Promotion Submarket 2014-2024
3.3.1 Contract Non-Personal Promotion: Submarket Forecast 2014-2024
3.3.1.1 Submarket Drivers and Restraints 2014-2024: Multichannel Marketing
3.3.2 Contract Teledetailing Submarket 2014-2024
3.3.2.1 Submarket Forecast 2014-2024: Rapid Growth in Demand for Contact Centres
3.3.2.2 Contract Teledetailing: Submarket Drivers and Restraints 2014-2024
3.3.3 Contract eDetailing Submarket 2014-2024
3.3.3.1 The Contract Edetailing Submarket Will Grow Fastest 2014-2024
3.3.3.2 Contract Edetailing: Submarket Drivers and Restraints 2014-2024
3.4 Medical Education Services Submarket 2014-2024
3.4.1 Medical Education Services Submarket: Revenue Forecast 2014-2024
3.4.2 Complex Drug Development to Drive Submarket Growth to 2024
3.5 Sample Management Services Submarket 2014-2024
3.5.1 Steady Growth for Sample Management Services top 2024
3.5.2 Sample Management Services: Submarket Drivers and Restraints 2014-2024
3.5.3 J. Knipper & Co.: A US Leader in Sample Management Services
3.5.3.1 J. Knipper Acquires Sample Management Divisions from Leading CSOs 2010-2013
3.5.3.2 New Technologies to Drive Growth 2014-2024
3.6 Chapter Summary: Continued High Demand for Contract Detailing Services for this Decade
4. Leading National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2014-2024
4.1 The Leading National Submarkets for Pharma Contract Sales 2012-2013
4.2 Leading National Pharma Contract Sales Submarkets: Outlook and Forecast 2014-2024
4.2.1 How Will Market Shares for Leading Countries Change to 2024?
4.3 Pharma Sales Regulatory Developments 2013-2024
4.3.1 Physician Payment Legislation in the US, Europe and Japan 2011-2014
4.3.1.1 The Physician Payment Sunshine Act (PPSA)
4.3.1.2 Physician Payments in France: Increased Scrutiny from 2013
4.3.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
4.3.2.1 Promotional Products in the EU: New Rules 2013
4.3.3 New Market Access Requirements in EU5 Nations 2011-2014
4.3.3.1 AMNOG: Stricter Pricing for Drugs in Germany
4.3.3.2 Healthcare Reform in France: Pricing and Reimbursement Set for Change?
4.3.3.3 Pricing Models and Clinical Commissioning Groups in the UK
4.3.4 Overtime for Sales Reps in the US: Rule Clarifications 2012-2013
4.4 The US Pharma Contract Sales Submarket 2014-2024
4.4.1 Pharma Sales Regulation in the US
4.4.2 US Submarket: Revenue Forecast 2014-2024
4.5 Pharma Contract Sales in the EU 2014-2024
4.5.1 Regulating Pharma Sales in the EU
4.5.2 Commercial Outlook for Pharma Contract Sales in the EU: Submarket Forecast 2014-2024
4.5.3 UK Submarket: Revenue Forecast 2014-2024
4.5.4 Strong Growth for the German Submarket to 2024
4.5.5 French Pharma Contract Sales Submarket: Revenue Forecast 2014-2024
4.5.6 Italian Submarket Forecast 2014-2024: Price Restrictions to Restrain Growth
4.5.7 Spanish Pharma Contract Sales Submarket: Revenue Forecast 2014-2024
4.6 Japanese Pharma Contract Sales: Regulatory and Commercial Outlook 2014-2024
4.6.1 Pharma Contract Sales in Japan 2012-2013
4.6.2 Rise in Outsourcing Rate to Drive Japanese Submarket Growth 2014-2024
4.7 Chapter Summary: Strong Growth for Leading National Submarkets 2014-2024
5. Emerging National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2014-2024
5.1 Pharma Contract Sales in Emerging National Submarkets 2012-2013
5.2 Outlook for Emerging National Submarkets: Revenue Forecasts 2014-2024
5.3 Improving Regulation for Pharma Sales in Emerging Markets
5.4 Pharma Contract Sales in China 2014-2024
5.4.1 Rising In-House and Outsourced Sales Rep Numbers 2011-2013
5.4.2 Concerns over Bribery in Chinese Pharma Sales 2013
5.4.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast 2014-2024
5.5 India: Pharma Contract Sales Submarket 2014-2024
5.5.1 New Pharma Sales Rules Proposed for 2014
5.5.2 Demand for Field Sales Teams to Drive Growth in the Indian Submarket Growth to 2024
5.6 Pharma Contract Sales in Brazil 2014-2024
5.6.1 State Payment Rules for Drugs in Brazil
5.6.2 Updated Online Marketing Rules for Prescription Drugs
5.6.3 Brazilian Pharma Contract Sales Submarket: Revenue Forecast 2014-2024
5.7 Pharma Contract Sales in Russia 2014-2024
5.7.1 New State Procurement Rules for Drugs 2013
5.7.2 Restricted Interactions between Doctors and Sales Reps in Russia
5.7.3 Russian Pharma Contract Sales Submarket: Revenue Forecast 2014-2024
5.8 Chapter Summary: Outlook for Pharma Contract Sales in Emerging Nations 2014-2024
6. Pharma Contract Sales: Industry and Market Trends 2014-2024
6.1 Pharma Contract Sales Market: Strengths and Weaknesses 2013
6.2 Pharma Contract Sales Market: Opportunities and Threats 2014-2024
6.3 Pharma Contract Sales Market: STEP Analysis 2014-2024
6.3.1 Social Factors Impacting Pharma Sales to 2024
6.3.1.1 The Role of Ethics in Pharma Sales
6.3.2 Technological Developments to Improve Sales Strategies
6.3.2.1 Smartphones and Tablets for New Detailing Strategies
6.3.2.2 Closed Loop Marketing (CLM)
6.3.2.3 Cloud Computing and its Use Pharma Contract Sales
6.3.2.4 Customer Relationship Management (CRM)
6.3.2.5 Can Big Data Play a Role in Pharma Sales?
6.3.2.6 How Will Pharma Use Social Media in Sales?
6.3.3 Economic Pressures Are Limiting Healthcare and Marketing Budgets
6.3.4 Political Issues: Stricter Regulations for Pharma Sales in Markets Worldwide
6.4 Major Trends in Outsourced Pharma Sales 2014-2024
6.4.1 Cuts to In-House Sales Staff Will Continue in this Decade
6.4.2 Strategic Partnering to Provide Long-Term Revenue Growth
6.4.3 Leading CSOs Will Consolidate to Increase Market Penetration
6.4.4 There Are Risks in Outsourcing Pharma Sales
6.5 Drug Development Trends Impacting Pharma Sales 2014-2024
6.5.1 How Will Orphan Drug Development Impact Pharma Sales?
6.5.2 Promotion for Biosimilar Drugs 2014-2024
6.5.3 There Will be Greater Demand for Specialty Medicine
6.5.4 The Appeal of Emerging Markets
6.6 New Sales Models Are Needed
6.6.1 Sales Reps Are Struggling for Access to Healthcare Professionals
6.6.2 Multichannel Marketing to Overcome Problems of Access
6.6.3 Key Account Management (KAM)
6.6.4 Silos in Sales and Marketing
6.6.5 The Use of Key Opinion Leaders (KOLs) in Pharma Sales to 2024
6.7 Market Access and Contract Pharma Sales
6.7.1 There Are Emerging Stakeholders in Pharma Sales
6.7.2 Changes in Market Access in the US 2014-2024: The Rise of ACOs
6.7.3 Market Access in the EU 2014-2024
6.7.4 The Role of CSOs in Improved Market Access
6.8 Chapter Summary: Key Trends Impacting Pharma Contract Sales 2014-2024
7. Leading Contract Sales Organisations (CSOs) 2014-2024
7.1 Few CSOs Compete on a Global Scale
7.2 Quintiles: World Market Leader for Contract Sales and Market Access
7.2.1 New Services and Strategic Partnerships
7.2.2 Quintiles Integrated Healthcare Services: Performance 2010-2013
7.2.3 Outlook for Quintiles’ Contract Sales 2014-2024
7.3 inVentiv Health
7.3.1 inVentiv is Expanding in Asia
7.3.2 inVentiv’s Commercial Services: Recent Financial Performance
7.3.3 inVentiv Health: Contract Sales Outlook 2014-2024
7.4 UDG Healthcare
7.4.1 Geographic and Service Growth through Acquisitions
7.4.2 UDG Healthcare: Financial Performance 2010-2013
7.4.3 A Leader in Europe 2014-2024?
7.5 North America: Leading Regional-Level CSOs 2013
7.5.1 PDI
7.5.1.1 Broad Service Portfolio 2013
7.5.1.2 New Sales Models for Medical Devices
7.5.1.3 Financial Performance 2010-2013
7.5.1.4 PDI: Contract Sales Outlook 2014-2024
7.5.2 Publicis Touchpoint Solutions
7.5.2.1 New Services 2011-2013
7.5.3 OnCall
7.5.3.1 OnCall Partners with Promius Pharma
7.6 Leading Domestic CSOs in Europe
7.6.1 Marvecs: A Local Leader in Germany
7.6.1.1 New Services Added 2012-2013: Sales 3.0
7.6.2 Sofip: Contract Sales for the French Submarket
7.7 CSOs in Asia Pacific
7.7.1 Global Leaders Dominate in Japan
7.7.2 CMIC Accounts for 10% of Outsourced Sales Reps in Japan
7.7.2.1 CMIC CSO: Financial Performance 2010-2013
7.7.3 Leading Players in China Are Not Just CSOs
7.8 Chapter Summary: Growth Strategies for Market Leaders 2014-2024
8. Research Interviews 2012-2014
8.1 Rick Keefer, President and CEO, and Michelle Keefe, COO, Publicis Touchpoint Solutions
8.1.1 Demand for Publicis’ Services
8.1.2 The Role of eDetailing in Pharma Sales
8.1.3 Technology and Pharma Sales
8.1.4 Trends in Drug Development and the Future of Pharma Contract Sales
8.2 Frank Saia, General Manager, Group DCA and Gerry Melillo, President, Sales Services, PDI
8.2.1 In-Demand Services CSOs in 2013
8.2.1.1 Multichannel Marketing Strategies and CSOs
8.2.2 Edetailing Uptake in 2013 and Future Directions
8.2.3 The Role of Technology in Pharma Sales
8.2.4 Rising Demand for Clinical Education Services?
8.2.5 The Future of Market Access in the US
8.3 Chris Anderson, Managing Director, Evolve Selection
8.3.1 Evolve Selection
8.3.2 There Are Benefits to Using CSOs for Market Access
8.3.2.1 Changing Demand for Market Access Services
8.3.3 Market Access in the UK
8.3.4 Sales Reps: Demand for New Skills
9. Conclusions to Our Study
9.1 The Pharma Contract Sales Market 2012-2013
9.1.1 Contract Detailing Services Dominate CSO Revenues in 2013
9.1.2 Spending on Contract Sales is Highest in the US and EU
9.2 Outlook for the Pharma Contract Sales Market 2014-2024
9.2.1 Growth Trends for Leading Submarkets 2014-2024
9.2.1.1 Therapeutic Sector Growth 2014-2024
9.2.2 Key Commercial Drivers for Pharma Contract Sales 2014-2024



List of Tables
Table 1.1 Sales as a Cost for Big Pharma Companies, 2012
Table 1.2 Currency Exchange Rates
Table 1.3 Benefits and Weaknesses to Outsourcing Pharma Sales
Table 1.4 Selected Big Pharma Sales Force Cuts, 2012-2013
Table 2.1 Leading CSO CAGRs (%), 2010-2013
Table 2.2 Pharma Contract Sales Market: Revenues ($bn), 2009-2013
Table 2.3 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Therapeutic Sector, 2012-2024
Table 2.4 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Therapeutic Sector, 2012
Table 2.5 Pharma Contract Sales Market: Therapeutic Submarket Shares (%), 2012-2024
Table 2.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2013-2024
Table 2.7 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2013-2024
Table 2.8 Selected Cancer Drugs Facing Market Access Challenges from NICE, 2011-2013
Table 2.9 Oncology Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Service Sector, 2012
Table 3.2 Contract Detailing Submarket: Revenues ($bn), 2010-2013
Table 3.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.4 Contract Non-Personal Promotion Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2012
Table 3.5 Contract Non-Personal Promotion: Overall Submarket and Revenue Forecasts ($bn) by Sector, 2012-2024
Table 3.6 Contract Non-Personal Promotion Submarket: Subsector Shares (%), 2012-2024
Table 3.7 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.8 Contract Edetailing Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.9 Medical Education Services Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.10 Sample Management Services Submarket: Revenue Forecast ($bn), 2013-2024
Table 3.11 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Service Sector, 2012-2024
Table 3.12 Pharma Contract Sales: Market Shares (%) by Service Sector, 2012-2024
Table 4.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Country, 2012
Table 4.2 Contract and In-House Sales Reps by Country, 2013
Table 4.3 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Region, 2012-2024
Table 4.4 Pharma Contract Sales: Market Shares (%) by Region, 2012-2024
Table 4.5 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2012
Table 4.6 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.7 US Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 4.8 EU Pharma Contract Sales Submarket: Revenues ($bn) and Submarket Shares (%) by Country, 2012
Table 4.9 EU Pharma Contract Sales Submarket: Overall Submarket and Revenue Forecasts ($bn) by Country, 2012-2024
Table 4.10 EU Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 4.11 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.12 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.13 Pharma Sales Rep Levels in France, 2007-2013
Table 4.14 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.15 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.16 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.17 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 4.18 Japanese Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 5.1 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) for Emerging Markets, 2012-2024
Table 5.2 Pharma Contract Sales: Emerging Market Shares (%), 2012-2024
Table 5.3 Chinese Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 5.4 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 5.5 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 5.6 Indian Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 5.7 Brazilian Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 5.8 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 5.9 Russian Pharma Contract Sales Submarket: Drivers and Restraints, 2014-2024
Table 5.10 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Table 6.1 Pharma Contract Sales Market: Strengths and Weaknesses, 2012-2013
Table 6.2 Pharma Contract Sales Market: Opportunities and Threats, 2014-2024
Table 6.3 Selected Blockbuster Patent Expiries, 2014-2016
Table 6.4 Pharma Contract Sales Market: STEP Analysis, 2014-2024
Table 6.5 Selected CRM Service Providers for Pharma Sales, 2013
Table 6.6 Biologic and Biosimilar Drug Markets: Revenue Forecasts ($bn), 2012, 2018 and 2024
Table 6.7 Orphan Drug Definitions in Leading Countries, 2013
Table 6.8 Orphan Drug Pipeline by Disease Area, 2011
Table 7.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2012-2013
Table 7.2 Quintiles: Emerging Market Entries: 2010-2012
Table 7.3 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2013
Table 7.4 inVentiv Health: Commercial Division Subsidiaries, 2013
Table 7.5 inVentiv Health: Commercial Revenue ($bn), 2010-2013
Table 7.6 UDG Healthcare: Contract Sales Subsidiaries, 2013
Table 7.7 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2013
Table 7.8 PDI: Revenue by Division ($bn), 2009-2012
Table 7.9 PDI: Revenue by Division ($bn), Q1-Q3 2012 and 2013
Table 7.10 Sofip: Revenue ($bn), 2010-2013
Table 7.11 CMIC: CSO Revenue ($bn), 2010-2013
Table 9.1 Pharma Outsourcing Market: Revenues ($bn) and Market Shares (%) by Sector, 2012
Table 9.2 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Service Sector, 2012, 2018 and 2024
Table 9.3 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Therapeutic Sector, 2012, 2018 and 2024
List of Figures
Figure 1.1 Services Offered by CSOs in the Pharma Contract Sales Market
Figure 1.2 Outsourcing in the Pharma Industry
Figure 1.3 Trends Driving the Need for New Sales Models, 2014-2024
Figure 2.1 Pharma Contract Sales Market: Revenues ($bn), 2009-2013
Figure 2.2 Pharma Contract Sales Market: Revenue Forecast ($bn), 2013-2024
Figure 2.3 Pharma Contract Sales: Market Drivers, 2014-2024
Figure 2.4 FDA: New Drug Approvals, 2007-2012
Figure 2.5 Pharma Contract Sales: Market Restraints, 2014-2024
Figure 2.6 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2012
Figure 2.7 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2018
Figure 2.8 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2024
Figure 2.9 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2013-2024
Figure 2.10 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2013-2024
Figure 2.11 Oncology Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.1 Pharma Contract Sales: Market Shares (%) by Service Sector, 2012
Figure 3.2 Contract Detailing Submarket: Revenues ($bn), 2010-2013
Figure 3.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.4 Contract Detailing Submarket: Drivers and Restraints, 2014-2024
Figure 3.5 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2012
Figure 3.6 Contract Non-Personal Promotion Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.7 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2018
Figure 3.8 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2024
Figure 3.9 Contract Non-Personal Promotion Submarket: Drivers and Restraints, 2014-2024
Figure 3.10 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.11 Contract Teledetailing Submarket: Drivers and Restraints, 2014-2024
Figure 3.12 Contract Edetailing Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.13 Contract Edetailing Submarket: Drivers and Restraints, 2014-2024
Figure 3.14 Medical Education Services Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.15 Medical Education Services Submarket: Drivers and Restraints, 2014-2024
Figure 3.16 Sample Management Services Submarket: Revenue Forecast ($bn), 2013-2024
Figure 3.17 Sample Management Services Submarket: Drivers and Restraints, 2014-2024
Figure 3.18 Pharma Contract Sales: Market Shares (%) by Service Sector, 2018
Figure 3.19 Pharma Contract Sales: Market Shares (%) by Service Sector, 2024
Figure 4.1 Pharma Contract Sales: Market Shares (%) by Country, 2012
Figure 4.2 Contract and In-House Sales Reps by Country, 2013
Figure 4.3 Pharma Contract Sales: Market Shares (%) by Region, 2018
Figure 4.4 Pharma Contract Sales: Market Shares (%) by Region, 2024
Figure 4.5 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2012
Figure 4.6 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.7 EU Pharma Contract Sales: National Submarket Shares (%), 2012
Figure 4.8 EU Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.9 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.10 Growing Rate of Outsourced Sales Reps in Germany, 2003-2013
Figure 4.11 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.12 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.13 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.14 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 4.15 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 5.1 Pharma Contract Sales: Emerging Market Shares (%), 2018
Figure 5.2 Pharma Contract Sales: Emerging Market Shares (%), 2024
Figure 5.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 5.4 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 5.5 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 5.6 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2013-2024
Figure 6.1 Biologic and Biosimilar Drug Markets: Revenue Forecasts ($bn), 2012, 2018 and 2024
Figure 6.2 Orphan Drug Pipeline by Disease Area, 2011
Figure 7.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2012-2013
Figure 7.2 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2013
Figure 7.3 inVentiv Health: Commercial Revenue ($bn), 2010-2013
Figure 7.4 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2013
Figure 7.5 PDI: Revenue by Division ($bn), 2009-2012
Figure 7.6 PDI: Revenue by Division ($bn), Q1-Q3 2012 and 2013
Figure 7.7 Sofip: Revenue ($bn), 2010-2013
Figure 7.8 CMIC: CSO Revenue ($bn), 2010-2013
Figure 9.1 Pharma Outsourcing Market: Market Shares (%) by Sector, 2012
Figure 9.2 Pharma Contract Sales Market: Revenue Forecast ($bn) by Service Sector, 2012, 2018 and 2024
Figure 9.3 Pharma Contract Sales Market: Revenue Forecast ($bn) by Therapeutic Sector, 2012, 2018 and 2024


【掲載企業】

AbbVie
Actavis
Accenture
Addison Whitney (part of inVentiv Health)
Adheris (part of inVentiv Health)
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) [France]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agenzia Italiana del Farmaco (AIFA)
Akcess
Akrikhin
Allergan
Alliance Healthcare (part of UDG Healthcare)
American Medical Association (AMA)
Apple
Arena Pharmaceuticals
Ashfield Healthcare (part of UDG Healthcare)
Ashfield Healthcare Ireland (part of UDG Healthcare)
Ashfield Healthcare USA (part of UDG Healthcare)
Ashfield In2Focus (part of UDG Healthcare)
Ashfield KK (part of UDG Healthcare)
Association of the British Pharmaceutical Industry (ABPI)
AstraZeneca
Bain Capital
Biogaran
Boehringer Ingelheim
Business Edge Solutions and Training (BEST, part of UDG Healthcare)
Catalina Health (part of Adheris)
Cegedim
Celesio
Centers of Medicare and Medicaid Services (CMS) [US]
Chandler Chicco (part of inVentiv Health)
CMIC
CMR Institute
Dayarn Pharma
Depomed
Drug Safety Alliance (DSA, part of UDG Healthcare)
Eisai
Eli Lilly
Endo Pharmaceuticals
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Promotional Product Association (EPPA)
Evolve Selection
Expansis (part of UDG Healthcare)
Express Scripts
Gesamtverband der Werbeartikel Wirtschaft e.V. (GWW) [Germany]
Go! Healthcare Marketing
Grey Healthcare Group
Group DCA (part of PDI)
GSW Worldwide (part of inVentiv Health)
Health Kare Pharma International
Hospira
IMS Health
Innovex (part of Quintiles)
InsightOut (part of inVentiv Health)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) [Germany]
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Interpace BioPharma (part of PDI)
Interpace Diagnostics (part of PDI)
inVentiv Creative Studios (part of inVentiv Health)
inVentiv Digital+Innovation (part of inVentiv Health)
inVentiv Health
inVentiv Health Korea (part of inVentiv Health)
inVentiv Japan (part of inVentiv Health)
inVentiv Media 360º (part of inVentiv Health)
inVentiv Medical Communications (part of inVentiv Health)
inVentiv Medical Management (part of inVentiv Health)
inVentiv Patient Access Solutions (part of inVentiv Health)
inVentiv Recruitment Services (part of inVentiv Health)
inVentiv Selling Solutions (part of inVentiv Health)
inVentiv Therapeutics Institute (part of inVentiv Health)
J&J
J. Knipper & Co.
Japan Contract Sales Organization Association (JCSOA)
Japan Pharmaceutical Manufacturers Association (JPMA)
JSA (part of inVentiv Health)
Kadrige
Les enterprises du médicament (LEEM) [France]
Lupin Pharmaceuticals
Marvecs
MDS Co. (part of CMIC)
Medical Communications Group (MCG, part of UDG Healthcare)
Medical Council of India (MCI)
Menarini Asia-Pacific (formerly Invida)
Menarini Group
Merck & Co.
Merqurio Pharma
Microsoft
Ministère des Affaires sociales et de la Santé [France]
Ministério da Saúde [Brazil]
Ministry of Health [China]
MKM Group
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
Neurocrine Biosciences
Norwegian Medicines Agency (NoMA)
NovaMed Pharmaceuticals
Novartis
Novo Nordisk
OnCall
Oracle
Organization of Pharmaceutical Producers of India (OPPI)
Otsuka Pharmaceutical
Palio+Ignite (part of inVentiv Health)
ParagonRx (part of inVentiv Health)
Patient Marketing Group (part of inVentiv Health)
PDI
PDI Voice (part of PDI)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmagistics (part of J. Knipper)
Pharmexx (part of UDG Healthcare)
Polpharma
Promius Pharma
Publicis Groupe
Publicis Health Communications Group
Publicis Touchpoint Solutions
Q.E.D International (part of Quintiles)
Qforma
Quintiles
Ramco Import Export
Roche
Salesforce.com
Sandoz (part of Novartis)
Sanofi
Scientific Voice (part of Publicis Touchpoint Solutions)
Sermo
Servier
Sinclair IS Pharma
Skype
Sofip (Société de Franchise pour l'Information Pharmaceutique)
StayinFront
Synopia Rx (part of UDG Healthcare)
Temas (part of Quintiles)
Temasek Holdings
Teva Pharmaceutical Industries
The Navicor Group (part of inVentiv Health)
Thomas H. Lee Partners
TPG
Transgenomic
UDG Healthcare
Universal WorldEvents (part of UDG Healthcare)
US Congressional Budget Office (CBO)
US Food and Drug Administration (FDA)
VCG & Associates (part of Quintiles)
Veeva Systems
Vivus
Warner Chilcott (part of Actavis)
World Health Organization (WHO)
WPP
Zuellig Group
Zuellig Pharma (part of Zuellig Group)


★調査レポート[世界の医薬品受託販売業界および市場(2014-2024)] ( World Pharma Contract Sales Industry and Market: Predictions 2014-2024 / Visiongain-4052628) 販売に関する免責事項
[世界の医薬品受託販売業界および市場(2014-2024)] ( World Pharma Contract Sales Industry and Market: Predictions 2014-2024 / Visiongain-4052628) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆